An in-depth interview with Dr. Tess Lawrie of EBMC Squared describing the effectiveness of long-time safe medicine ivermectin to treat and prevent covid and how health authorities are systematically ignoring the evidence.
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Most Covid studies have not considered days of therapy, cumulative dose, or weight-adjusted dosing. We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients. By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot. However, given the data presented here, the studies reporting HCQ’s effect of QTc intervals need to be re-evaluated.
Medical experts from around the world joined together to present the very latest real world research on repurposing this safe drug that has the ability to transform global efforts to fight the pandemic. Prof. Pierre Kory discusses current protocols for covid-19 prevention and treatment.
The International Ivermectin for Covid Conference: Professor Eli Schwartz shares data and conclusions from his Israeli randomised controlled trial of ivermectin in mild to moderate covid-19.
The International Ivermectin for Covid Conference:
Dr. Tess Lawrie presents the latest systematic review evidence from RCTs and a selection of resource, equity, acceptability and feasibility considerations related to ivermectin use for COVID-19
With a surge of SARS-CoV-2 infections and a vaccination drive totaling 1.3 million, the nation’s leadership faces an uphill battle when factoring in their total population of 108 million. Hence the growing interest in ivermectin and the request of hospitals for access to the drug for compassionate use.
NIH will provide an initial investment of $155 million in funding for the trial. TrialSite picked up inside rumblings that ivermectin will be one of the economical drugs under investigation. While this study is late in the pandemic, nonetheless TrialSite celebrates Collins and team’s movement in this most important of areas. We don’t currently have approved medication to be self-administered by people suffering mild disease at home & reduce the chance of needing hospitalization.
FLCCC Weekly Update: “Big Science vs Little Science”—April 14, 2021 Drs. Jose Morgenstern and Jose Redondo of the Dominican Republic share their new ivermectin study and tell the story of how they discovered the efficacy of ivermectin in April, 2020.
Source: Rounding the Earth Author: Mathew Crawford The story of why hydroxychloroquine (HCQ) has not been used broadly in most Western nations (primarily in the
WMA DECLARATION OF HELSINKI – ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS
Hydroxychloroquine + azithromycin had a significant effect on COVID-19 infected patients length of stay in the hospital.
Dr. John Campbell Belgium, not Dutch. Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants (International Journal
Use of chloroquine (tablets) is showing favorable outcomes in humans infected with Coronavirus including faster time to recovery and shorter hospital stay.
HCQ Studies are overwhelmingly positive, negative studies get lots of attention but have some serious flaws.
HCQ use significantly reduced the mortality rate, but this association was found only in the lowest cumulative dosage exposure group.
Source: Fox News Researchers at the Henry Ford Health System in Southeast Michigan have found that early administration of the drug hydroxychloroquine makes hospitalized patients substantially
Source: Henry Ford Health System DETROIT – Treatment with hydroxychloroquine cut the death rate significantly in sick patients hospitalized with COVID-19 – and without heart-related side-effects,
Source: International Journal of Infectious Diseases Highlights As of May27, 2020 there are over 1,678,843 confirmed cases of COVID-19 claiming more than 100,000 lives in
No life-threatening modifications of the QT interval was observed in non-severe COVID-19 patients treated ambulatory with hydroxychloroquine and azithromycin. Studies are needed in critical-ill and older patients.
The clinical trials on this list are studying Hydroxychloroquine. All trials on the list are supported by NCI.
Origial Source: FranceSoir In the Recovery and Solidarity clinical trials, it is not excluded that patients died as a result of a therapeutic overdose of
It treats patients in the initial phase, if the patient is medicated at the very beginning of the symptoms, the disease may not reach the acute phase, where the use of respirators is necessary.
How can we trust the established authorities or prestigious journals when, in this perilous time, trials of an available, inexpensive, long-established drug appear to be designed to fail, while risking the lives of their subjects through deliberate or negligent drug overdoses?
A Sungai Buloh Hospital clinician also described the controversial antimalarial drug, hydroxychloroquine, as an anchor during the peak of the Covid-19 crisis in Malaysia.
The study, which was obviously flawed on its face (I commented well before it was exposed that the groupings made no sense), turned out to be produced by a shell company, with unverified data gathered by non-scientists.
None of the patients died in the studied period and only 6 have to be admitted in conventional hospitalization area.
Source: MedRxiv Abstract: The new SARS-CoV-2 infection named COVID-19 has severely hit our Health System. At the time of writing this paper no medical therapy
Source: Jakarta Globe Researchers from Airlangga University, Government’s Covid-19 Task Force, and State Intelligence Agency (BIN) have claimed to have found combinations of medicine that effectively reduce the
Source: Pan American Health Organisation Importance: Patients in long-term care facilities (LTCF) are at a high-risk of contracting COVID-19 due to advanced age and multiple
Source: Times of India Nagpur: Preventive measures taken by city police’s medical teams seemed to have worked better for them in comparison to their counterparts
Source: The Guardian The World Health Organization and a number of national governments have changed their Covid-19 policies and treatments on the basis of flawed data from
Source: statnews The World Health Organization is resuming a clinical trial exploring whether the malaria drug hydroxychloroquine can effectively treat Covid-19, after pausing enrollment in
Source: Preprints.org The challenge regarding COVID-19 is to prevent complications and fatal evolution. Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro.
Source: France Soir Surgisphere is the company responsible for collecting data from Professor Mehra’s study, which has received worldwide attention for the past 7 days. After our first interview
Source: Medicine Uncensored by James M Todaro, MD (Columbia MD, @JamesTodaroMD)May 29, 2020, (updated May 30, 2020) Misinformation is bad. Misinformation in medicine is worse. Misinformation from a
Source: Brasil Sem Medo Study that rejects hydroxychloroquine use in Covid-19 patients is not science, but instrumentalization of science. The twilight of quinine A study
Source: Medrxiv View ORCID Profile Amanda Chamieh, Claude Afif, View ORCID Profile Gerard El-Hajj, View ORCID Profile Omar Zmerli, Isabelle Djaffar-Jureidini,View ORCID Profile Roy A. Raad, Raja Ashou, George Juvelekian,View ORCID Profile Jean-Marc Rolain,View ORCID Profile Eid Azar doi: https://doi.org/10.1101/2020.05.28.20114835 This article
Source: Le Devoir Canada Following the publication of the results of a large study indicating that administration of chloroquine or hydroxychloroquine alone or in combination
